Medical decisions for people with an inherited NBN mutation who have been diagnosed with cancer
Currently there are no cancer treatments approved specifically for people with a NBN mutation, nor guidelines for treating cancer specifically for people with a NBN mutation. To learn more about standard of care treatment options for specific types of cancer, visit our section on Cancer Treatment by Cancer Type. You may also consider enrolling in a clinical trial studying which treatments work best for people with an inherited NBN mutation.
If you are a person with an NBN mutation, you can find peer support through the following resources:
- Register for the FORCE Message Boards to connect with others who share your situation. Once you register, you can post on the Share Your Mutation board or the Diagnosed with Cancer board to connect with other people who carry an NBN mutation.
- FORCE's Peer Navigation Program will match you with a volunteer who shares your mutation and situation and provide you with a free resource guide.
- Contact the FORCE impact leaders in your area to link to local support groups and other resources.
- Attend a virtual support meeting in your area.
- Read the stories from members of our community.
The following cancer treatment studies are open to people with an NBN mutation.
Advanced solid tumors of any type
- NCT03718091: M6620 (VX-970) in Selected Solid Tumors. This is a phase 2 study looking at M6620, a drug designed to inhibit the ATR enzyme. Inhibiting ATR may block how cancers repair their damaged DNA. The study is specifically enrolling patients with NBN mutations in their tumor.
- NCT04171700: A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes (LODESTAR). This study is evaluating the response of rucaparib in patients with various solid tumors and with certain tumor mutations in Homologous Recombination Repair (HRR) genes, including NBN.
- NCT03344965: A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded). Olaparib (Lynparza) is a type of treatment known as a PARP inhibitor, which is approved for metastatic breast cancer in people with a BRCA mutation. This study is looking at how well olaparib works in people with an NBN or other mutation.
- NCT02401347: Talazoparib Beyond BRCA (TBB) Trial. People with an ATM mutation who have metastatic triple-negative breast cancer may qualify for this study. Talazoparib (Talzenna) is a type of treatment known as a PARP inhibitor, which is approved for metastatic breast cancer in people with a BRCA mutation. This study is looking at how well talazoparib works in people with an NBN or other mutation.
- NCT04030559: Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects. This trial studies how well niraparib, when given before surgery, works in treating patients with high risk prostate cancer that has not spread to other parts of the body.
- NCT03012321: Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects. This is a phase II study in men with metastatic castration resistant prostate cancer (mCRPC) open to men with an NBN or other mutation.
Visit our Research Search and Enroll Tool to find additional cancer treatment studies.